Loading
HB
Heat Biologics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by KHARITONOV MICHAEL, was filed 23 Mar 2016.
Heat Biologics, Inc.: what insiders have been doing
Headquartered in Durham, United States, Heat Biologics, Inc. belongs to the Healthcare & Pharma sector and traces its origins to 2008. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Heat Biologics, Inc. The previous disclosure was published on 17 May 2024.
Our records for Heat Biologics, Inc. go back to 2016, with 1 purchase and 2 sales on the open market in total.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
30
Thresholds
n/a
Buy Volume
€601,445
1 ops. · all time
Sell Volume
€260,305
2 ops. · all time
Since the insiders bought
- +20.6%Entry US$9,922.33 · Close at T+365 US$11,965.94
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$6.2M
Gross profitUS$3M49% margin
EBITDA-US$26.2M-420% margin
Net income-US$32.8M-525.5% margin
Valuation
Beta-5.33
Balance sheet & cash
Total debtUS$28.5M
Free Cash Flow-US$26.9M
Profitability & ownership
ROE-303.4%
ROA-47.9%
% insiders0.0%
% institutions0.0%
Last declaration on 17 May 2024
Declarations30 total
2,500,000 sharesCommon StockSEC:0001079973-24-000776:0
246,305 shares0Common StockSEC:0001553350-21-001169:0
35,000 shares@ US$5.8655100.0% of flowCommon StockSEC:0001553350-21-000431:0
138,272 shares0Common StockSEC:0001553350-21-000008:0
288,100 shares0Common StockSEC:0001553350-21-000010:0
103,304 shares@ US$1.03100.0% of flowCommon StockSEC:0001553350-20-001008:0
15,625 shares@ US$0.5250.0% of flowCommon StockSEC:0001553350-20-000759:0
4,440 shares@ US$1.8350.0% of flowCommon StockSEC:0001553350-20-000759:1
900,000 shares0Common StockSEC:0001553350-20-000007:0
400,000 shares0Common StockSEC:0001553350-20-000003:0
800,000 shares0Common StockSEC:0001553350-20-000001:0
900,000 shares0Common StockSEC:0001553350-20-000002:0
1,980,000 shares0Common StockSEC:0001553350-20-000002:1
800,000 shares0Common StockSEC:0001553350-19-000009:0
300,000 shares0Common StockSEC:0001553350-19-000010:0
143,140 shares0Common StockSEC:0001553350-19-000006:0
89,430 shares0Common StockSEC:0001553350-19-000008:0
665,720 shares0Common StockSEC:0001553350-18-000033:0
45,000 shares0Common StockSEC:0001553350-18-000031:0
10,010 sharesCommon StockSEC:0001553350-17-000462:0
335,743 sharesCommon StockSEC:0001553350-17-000462:1
16,349 sharesCommon StockSEC:0001553350-17-000463:0
76,070 sharesCommon StockSEC:0001553350-17-000463:1
179,333 sharesCommon StockSEC:0001553350-17-000463:2
3,958 sharesCommon StockSEC:0001553350-17-000461:0
25 of 30 declarations
About Heat Biologics, Inc.
Heat Biologics, Inc. is a U.S.-listed biotechnology company historically associated with the NASDAQ (ticker HTBX), and it has been followed by investors through its SEC Form 4 insider filings. For French-speaking investors in Europe, the company is best understood as a small-cap U.S. biotech with a classic development-stage risk profile: its valuation has been driven far more by pipeline execution, intellectual-property optionality, and financing capacity than by stable commercial revenues. The company was incorporated in 2008 in Delaware and operated for years from Morrisville, North Carolina, in the Research Triangle / Research Triangle Park life-sciences cluster. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1476963/000155335017000337/htbx_10k.htm?utm_source=openai))
At its core, Heat Biologics was originally built around immunotherapy programs designed to stimulate the immune system against cancer, including T-cell activation approaches. SEC materials describe a pipeline that included programs such as HS-110 and PTX-35, along with a proprietary biologics discovery platform and supporting capabilities in biologics manufacturing, immunoassays, cell-based assays, and biomarker work. The company also explored biodefense-adjacent and vaccine-related opportunities, reflecting a strategy centered on platform technology and multiple shots on goal rather than a single commercial product. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1476963/000155335022000012/htbx_ex99z1.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Heat Biologics operated in one of the most crowded and capital-intensive parts of healthcare: oncology and immunology biotech. Its competitive edge was not scale, but the potential value of differentiated assets, the breadth of its scientific platform, and the possibility of partnering or monetizing programs at key development milestones. As with most clinical-stage biotech names, the main investment risks have been clinical failure, regulatory setbacks, dilution risk, and the need to continuously secure funding for research and development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1476963/000155335022000012/htbx_ex99z1.htm?utm_source=openai))
Recent corporate history is especially important. SEC filings show that Heat Biologics changed its name to NightHawk Biosciences in 2022, and later to Scorpius Holdings in 2024, as the group evolved away from its original pure-play therapeutic identity and toward a more vertically integrated model including contract development and manufacturing. The company’s SEC disclosures also show the sale of the Elusys Therapeutics assets in late 2023, highlighting an active portfolio reshaping. For investors tracking legacy Form 4 insider activity under the name Heat Biologics, Inc., this means the historical issuer name may not fully reflect the company’s current corporate form or strategic emphasis. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1476963/000155837023005289/nhwk-20221231x10k.htm?utm_source=openai))
In short, Heat Biologics, Inc. represents a high-risk, high-optional-value U.S. healthcare investment case rooted in the United States and associated with the NASDAQ. The company’s story has moved from immuno-oncology development toward a broader biologics and manufacturing footprint, making it important to distinguish between its legacy pipeline identity and its more recent corporate transformation when interpreting insider transactions and market disclosures. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1476963/000155335022000012/htbx_ex99z1.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
